Nephrology and Hypertension Associates, LTD

Frenova Renal Research

Kidney Diseases

Anemia

Type 2 Diabetes Mellitus

Focal Segmental Glomerulosclerosis

Hyperphosphatemia

Chronic Renal Insufficiency

Chronic Kidney Failure

VX-147

Tenapanor

Finerenone

Phosphate

Vertex Pharmaceuticals

Ardelyx

Bayer

Celgene

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease

Frenova Renal Research | Nephrology and Hypertension Associates, LTD

Site insights

Work at this site?

Active trials

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease (AMPLITUDE)

Trial sponsors